Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

Ting Chang Chang,H S Shiah,C. H. Yang,Kun-Huei Yeh,Ann-Lii Cheng,B. N. Shen,Y.W. Wang,C G Yeh,N. J. Chiang,Jang-Yang Chang,Li-Tzong Chen

Phase i study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients

2015

Ting Chang Chang
H S Shiah
C. H. Yang
Kun-Huei Yeh
Ann-Lii Cheng
B. N. Shen
Y.W. Wang
C G Yeh
N. J. Chiang
Jang-Yang Chang
Li-Tzong Chen

Purpose To define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and pharmacokinetics (PK) of PEP02, a novel liposome-encapsulated irinotecan, in patients with advanced refractory solid tumors.

Keywords:

Irinotecan sucrosofate
Refractory
Advanced Solid Tumor
Pharmacology
Irinotecan
Maximum tolerated dose
Toxicity
Pharmacokinetics
Medicine
Camptothecin
phase i study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations